Neurotoxic events associated with BCR-ABL1 tyrosine kinase inhibitors: a case series

Leuk Lymphoma. 2019 Dec;60(13):3292-3295. doi: 10.1080/10428194.2019.1633635. Epub 2019 Jun 27.

Affiliations

¹ Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
² Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
³ Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
⁴ Departement of Stem Cell Transplant and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

PMID: 31246142
DOI: 10.1080/10428194.2019.1633635

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Aged
Dasatinib / adverse effects
Female
Fusion Proteins, bcr-abl / antagonists & inhibitors*
Fusion Proteins, bcr-abl / genetics
Humans
Imatinib Mesylate / adverse effects
Intervertebral Disc Degeneration / chemically induced*
Intervertebral Disc Degeneration / diagnosis
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics
Male
Myelitis, Transverse / chemically induced*
Myelitis, Transverse / diagnosis
Optic Neuritis / chemically induced*
Optic Neuritis / diagnosis
Protein Kinase Inhibitors / adverse effects*

Substances

BCR-ABL1 fusion protein, human
Protein Kinase Inhibitors
Imatinib Mesylate
Fusion Proteins, bcr-abl
Dasatinib